Abstract
Developing an acetaminophen-free, immediate-release hydrocodone product remains an unmet medical need; however, new opioid analgesics should not introduce new abuse risks. Benzhydrocodone is a prodrug of hydrocodone that must be metabolized into hydrocodone by enzymes in the intestinal tract to optimally deliver its pharmacologic effects. This study evaluated the intranasal pharmacokinetics and abuse potential of benzhydrocodone active pharmaceutical ingredient (API) compared with hydrocodone bitartrate (HB) API. Single-center, randomized, double-blind, crossover study. Clinical research site. Healthy adult, nondependent, recreational opioid users. Subjects (N = 51 Completers) were randomized to receive 13.34 mg of intranasal benzhydrocodone API and 15.0 mg of intranasal HB API (molar-equivalent doses of hydrocodone). Blood samples were taken, and Drug Liking scores (assessed on a bipolar visual analog scale) were obtained throughout each dosing interval. Nasal irritation and safety were assessed. Peak hydrocodone plasma concentration (Cmax) was 36.0% lower, and total hydrocodone exposures (AUClast and AUCinf) were 20.3% and 19.5% lower, respectively, for benzhydrocodone API compared with HB API (P < 0.0001). All partial AUC va...Continue Reading
References
Apr 1, 1978·Archives of General Psychiatry·D R JasinskiJ D Griffith
Dec 1, 1980·Clinical Pharmacology and Therapeutics·J H JaffeJ Green
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N ChernyUNKNOWN Expert Working Group of the European Association of Palliative Care Network
Aug 9, 2001·Journal of Clinical Pharmacy and Therapeutics·R B Raffa
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Robert B RaffaAlbert I Wertheimer
Mar 23, 2004·Current Cancer Drug Targets·Russell D Petty, J Cassidy
Jun 14, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Julia RileyKen Welsh
Nov 3, 2007·The American Journal of Psychiatry·Deni CariseKevin G Lynch
Jul 9, 2008·Drug and Alcohol Dependence·Sharon L WalshJoseph R Holtman
Feb 27, 2009·Expert Opinion on Investigational Drugs·Lynn R WebsterRobert A Medve
Sep 10, 2009·Journal of Opioid Management·Sandra D ComerRichard W Foltin
Jul 29, 2010·Psychopharmacology·William W StoopsSharon L Walsh
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Oct 21, 2011·Harm Reduction Journal·Stephen F ButlerSimon H Budman
Apr 11, 2013·Paediatric Anaesthesia·Ivan WongSuellen M Walker
Feb 5, 2016·The New England Journal of Medicine·Robert M CaliffStephen Ostroff
Jun 16, 2016·Journal of Pain & Palliative Care Pharmacotherapy· Food And Drug Administration Public Health Service U S Department Of Health And Human Services
Sep 7, 2016·Pharmacoepidemiology and Drug Safety·Theodore J CiceroZachary A Kasper
Dec 10, 2016·PloS One·Janetta L IwanickiRichard C Dart
Apr 18, 2017·Drug and Alcohol Dependence·Jody L GreenRichard C Dart